Recent Updates
Recently added Catalysts
RVTY Positive Sentiment

Revvity Announces Financial Results for the Second Quarter of 2026

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Revvity, Inc. reported its financial results for Q2 2026, showing a slight increase in GAAP earnings per share to $0.48 from $0.47 in the previous year. Revenue also rose to $730 million compared to $720 million in the same quarter last year. The company reported an operating income of $89 million.

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue increased to $730 million from $720 million year-over-year.
  • GAAP earnings per share improved slightly from $0.47 to $0.48.
  • Operating income remains strong at $89 million.

Full Press Release Details

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue for the quarter was $730 million, as compared to $720 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related

Frequently Asked Questions

What were Revvity's earnings per share for Q2 2026?

Revvity reported GAAP earnings per share of $0.48 for Q2 2026.

How much revenue did Revvity generate in Q2 2026?

Revvity generated $730 million in revenue for Q2 2026.

What was Revvity's operating income for Q2 2026?

The operating income for Revvity in Q2 2026 was $89 million.

How does Q2 2026 revenue compare to last year?

Q2 2026 revenue increased from $720 million to $730 million compared to last year.

ShareAdd on Google
Tags: RVTY Viatris Investor Conferences Healthcare Revvity financial results Q2 2026 earnings report revenue growth
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$860M liquidity · $0M/mo burn
Low dilution risk